These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 16527427

  • 1. Therapeutic potentials of aspirin in glaucomatous optic neuropathy.
    Attarzadeh A, Hosseini H, Nowroozizadeh S.
    Med Hypotheses; 2006; 67(2):375-7. PubMed ID: 16527427
    [Abstract] [Full Text] [Related]

  • 2. [Retinal ganglion cells death in glaucoma--mechanism and potential treatment. Part I].
    Rokicki W, Dorecka M, Romaniuk W.
    Klin Oczna; 2007; 109(7-9):349-52. PubMed ID: 18260296
    [Abstract] [Full Text] [Related]

  • 3. Optic nerve and neuroprotection strategies.
    Osborne NN, Chidlow G, Layton CJ, Wood JP, Casson RJ, Melena J.
    Eye (Lond); 2004 Nov; 18(11):1075-84. PubMed ID: 15534592
    [Abstract] [Full Text] [Related]

  • 4. [Glaucoma as primary optic neuropathy].
    Nicolae A, Stefan C.
    Oftalmologia; 2001 Nov; 54(4):5-8. PubMed ID: 12035602
    [Abstract] [Full Text] [Related]

  • 5. [The dawn of neuroprotective therapy for glaucomatous optic neuropathy].
    Yamamoto T.
    Nippon Ganka Gakkai Zasshi; 2001 Dec; 105(12):866-83. PubMed ID: 11802458
    [Abstract] [Full Text] [Related]

  • 6. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma.
    Hains BC, Waxman SG.
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4164-9. PubMed ID: 16249495
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Retinal ganglion cells death in glaucoma--mechanism and potential treatment. Part II].
    Rokicki W, Dorecka M, Romaniuk W.
    Klin Oczna; 2007 Nov; 109(7-9):353-5. PubMed ID: 18260297
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Disease progression and the need for neuroprotection in glaucoma management.
    Varma R, Peeples P, Walt JG, Bramley TJ.
    Am J Manag Care; 2008 Feb; 14(1 Suppl):S15-9. PubMed ID: 18284311
    [Abstract] [Full Text] [Related]

  • 11. [Contemporary possibilities and perspectives in the treatment of glaucoma].
    Czepita D.
    Ann Acad Med Stetin; 2005 Feb; 51(1):27-31. PubMed ID: 16496599
    [Abstract] [Full Text] [Related]

  • 12. The potential value of natural antioxidative treatment in glaucoma.
    Mozaffarieh M, Grieshaber MC, Orgül S, Flammer J.
    Surv Ophthalmol; 2008 Feb; 53(5):479-505. PubMed ID: 18929760
    [Abstract] [Full Text] [Related]

  • 13. Molecular and cell-based approaches for neuroprotection in glaucoma.
    Lebrun-Julien F, Di Polo A.
    Optom Vis Sci; 2008 Jun; 85(6):417-24. PubMed ID: 18521011
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pathogenesis of ganglion "cell death" in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria.
    Osborne NN.
    Prog Brain Res; 2008 Jun; 173():339-52. PubMed ID: 18929120
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Neuroprotection in glaucoma - Is there a future role?
    Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF.
    Exp Eye Res; 2010 Nov; 91(5):554-66. PubMed ID: 20800593
    [Abstract] [Full Text] [Related]

  • 19. Current understanding of neuroprotection in glaucoma.
    Wein FB, Levin LA.
    Curr Opin Ophthalmol; 2002 Apr; 13(2):61-7. PubMed ID: 11880717
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.